What Certara, Inc. does.

We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development (“MIDD”) in the global biopharmaceutical and biotech industry. MIDD is an approach that utilizes biological and statistical models derived from preclinical, clinical, and evidence data to inform decision-making in drug research and development, and commercialization. Biosimulation is a critical component of MIDD that uses computer-aided mathematical simulation of biological processes and systems to understand the action of a drug in a human body or a population of humans.

Biosimulation and hereby MIDD can increase the probability of success in bringing a new drug to market, accelerate its development and decrease the costs of drug development. There are many examples of currently approved drugs where models were successfully used in discovery, preclinical, first-in-human dose predictions, clinical trial simulations and protocol design, and for drug interaction label claims. Biosimulation is also used to support drug development beyond the approval stage; examples include determining formulation or manufacturing changes and label extensions. In addition, MIDD strategies are increasingly utilized to help predict commercial success, a critical part of the drug research and development process as new products must be both approved by regulators and adopted by the market.

Revenue and profit, by fiscal year.

More on CERT.

• Certara, Inc. summary
• Certara, Inc. financial statements
• Certara, Inc. key metrics
• Certara, Inc. health scores and style box
• Certara, Inc. earnings
• Certara, Inc. dividends
• Certara, Inc. valuation
• Certara, Inc. ownership and insiders
• Certara, Inc. peers

Figures from Certara, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.